Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, Administered Intravenously and Orally in Healthy Participants
| العنوان: | Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, Administered Intravenously and Orally in Healthy Participants |
|---|---|
| المؤلفون: | Pamela L. Clemens, Shariq Syed, Arindam Dhar, Ian Walters, Eric Masson, Deanne Lathers, Georgia Kollia |
| المصدر: | The Journal of Clinical Pharmacology. 52:914-921 |
| بيانات النشر: | Wiley, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Adult, Male, Patient Dropouts, genetic structures, Midazolam, Administration, Oral, Antineoplastic Agents, Pharmacology, chemistry.chemical_compound, Pharmacokinetics, Oral administration, medicine, Cytochrome P-450 CYP3A, Humans, Drug Interactions, Prodrugs, Pharmacology (medical), Alanine, Cross-Over Studies, Dose-Response Relationship, Drug, CYP3A4, Triazines, business.industry, Middle Aged, Prodrug, Crossover study, Fibroblast Growth Factors, Intestines, Receptors, Vascular Endothelial Growth Factor, Brivanib alaninate, Liver, Tolerability, chemistry, Injections, Intravenous, Cytochrome P-450 CYP3A Inhibitors, Female, Metabolic Detoxication, Phase I, business, Half-Life, medicine.drug |
| الوصف: | Brivanib alaninate is the orally available prodrug of brivanib, a dual inhibitor of fibroblast growth factor and vascular endothelial growth factor signaling pathways that is under therapeutic investigation for various malignancies. Brivanib alaninate inhibits CYP3A4 in vitro, and thus there is potential for drug-drug interaction with CYP3A4 substrates, such as midazolam. The present study evaluated pharmacokinetic parameters and safety/tolerability upon coadministration of brivanib alaninate and midazolam. Healthy participants received intravenous (IV) or oral midazolam with and without oral brivanib alaninate. Blood samples for pharmacokinetic analysis were collected up to 12 hours after midazolam and up to 48 hours after brivanib alaninate. Twenty-four participants were administered study drugs; 21 completed the trial. No clinically relevant effect of brivanib alaninate on the overall exposure to midazolam following IV or oral administration was observed. Orally administered brivanib alaninate was generally well tolerated in the presence of IV or oral midazolam. The lack of a pharmacokinetic interaction between brivanib and midazolam indicates that brivanib alaninate does not influence either intestinal or hepatic CYP3A4 and confirms that brivanib alaninate may be safely coadministered with midazolam and other CYP3A4 substrates. |
| تدمد: | 0091-2700 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcaebc4588223e4e66de77c03ed910fcTest https://doi.org/10.1177/0091270011407495Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....dcaebc4588223e4e66de77c03ed910fc |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....dcaebc4588223e4e66de77c03ed910fc 796 3 unknown 796.05078125 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....dcaebc4588223e4e66de77c03ed910fc&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, Administered Intravenously and Orally in Healthy Participants
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Pamela+L%2E+Clemens%22">Pamela L. Clemens</searchLink><br /><searchLink fieldCode="AR" term="%22Shariq+Syed%22">Shariq Syed</searchLink><br /><searchLink fieldCode="AR" term="%22Arindam+Dhar%22">Arindam Dhar</searchLink><br /><searchLink fieldCode="AR" term="%22Ian+Walters%22">Ian Walters</searchLink><br /><searchLink fieldCode="AR" term="%22Eric+Masson%22">Eric Masson</searchLink><br /><searchLink fieldCode="AR" term="%22Deanne+Lathers%22">Deanne Lathers</searchLink><br /><searchLink fieldCode="AR" term="%22Georgia+Kollia%22">Georgia Kollia</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>The Journal of Clinical Pharmacology</i>. 52:914-921 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Wiley, 2012. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2012 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Patient+Dropouts%22">Patient Dropouts</searchLink><br /><searchLink fieldCode="DE" term="%22genetic+structures%22">genetic structures</searchLink><br /><searchLink fieldCode="DE" term="%22Midazolam%22">Midazolam</searchLink><br /><searchLink fieldCode="DE" term="%22Administration%2C+Oral%22">Administration, Oral</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Agents%22">Antineoplastic Agents</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology%22">Pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%2Echemical%5Fcompound%22">chemistry.chemical_compound</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacokinetics%22">Pharmacokinetics</searchLink><br /><searchLink fieldCode="DE" term="%22Oral+administration%22">Oral administration</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Cytochrome+P-450+CYP3A%22">Cytochrome P-450 CYP3A</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Interactions%22">Drug Interactions</searchLink><br /><searchLink fieldCode="DE" term="%22Prodrugs%22">Prodrugs</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology+%28medical%29%22">Pharmacology (medical)</searchLink><br /><searchLink fieldCode="DE" term="%22Alanine%22">Alanine</searchLink><br /><searchLink fieldCode="DE" term="%22Cross-Over+Studies%22">Cross-Over Studies</searchLink><br /><searchLink fieldCode="DE" term="%22Dose-Response+Relationship%2C+Drug%22">Dose-Response Relationship, Drug</searchLink><br /><searchLink fieldCode="DE" term="%22CYP3A4%22">CYP3A4</searchLink><br /><searchLink fieldCode="DE" term="%22Triazines%22">Triazines</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Prodrug%22">Prodrug</searchLink><br /><searchLink fieldCode="DE" term="%22Crossover+study%22">Crossover study</searchLink><br /><searchLink fieldCode="DE" term="%22Fibroblast+Growth+Factors%22">Fibroblast Growth Factors</searchLink><br /><searchLink fieldCode="DE" term="%22Intestines%22">Intestines</searchLink><br /><searchLink fieldCode="DE" term="%22Receptors%2C+Vascular+Endothelial+Growth+Factor%22">Receptors, Vascular Endothelial Growth Factor</searchLink><br /><searchLink fieldCode="DE" term="%22Brivanib+alaninate%22">Brivanib alaninate</searchLink><br /><searchLink fieldCode="DE" term="%22Liver%22">Liver</searchLink><br /><searchLink fieldCode="DE" term="%22Tolerability%22">Tolerability</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%22">chemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Injections%2C+Intravenous%22">Injections, Intravenous</searchLink><br /><searchLink fieldCode="DE" term="%22Cytochrome+P-450+CYP3A+Inhibitors%22">Cytochrome P-450 CYP3A Inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Metabolic+Detoxication%2C+Phase+I%22">Metabolic Detoxication, Phase I</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22Half-Life%22">Half-Life</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Brivanib alaninate is the orally available prodrug of brivanib, a dual inhibitor of fibroblast growth factor and vascular endothelial growth factor signaling pathways that is under therapeutic investigation for various malignancies. Brivanib alaninate inhibits CYP3A4 in vitro, and thus there is potential for drug-drug interaction with CYP3A4 substrates, such as midazolam. The present study evaluated pharmacokinetic parameters and safety/tolerability upon coadministration of brivanib alaninate and midazolam. Healthy participants received intravenous (IV) or oral midazolam with and without oral brivanib alaninate. Blood samples for pharmacokinetic analysis were collected up to 12 hours after midazolam and up to 48 hours after brivanib alaninate. Twenty-four participants were administered study drugs; 21 completed the trial. No clinically relevant effect of brivanib alaninate on the overall exposure to midazolam following IV or oral administration was observed. Orally administered brivanib alaninate was generally well tolerated in the presence of IV or oral midazolam. The lack of a pharmacokinetic interaction between brivanib and midazolam indicates that brivanib alaninate does not influence either intestinal or hepatic CYP3A4 and confirms that brivanib alaninate may be safely coadministered with midazolam and other CYP3A4 substrates. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 0091-2700 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcaebc4588223e4e66de77c03ed910fc" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcaebc4588223e4e66de77c03ed910fc</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1177/0091270011407495" linkWindow="_blank">https://doi.org/10.1177/0091270011407495</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....dcaebc4588223e4e66de77c03ed910fc ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 8
[StartPage] => 914
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[1] => Array
(
[SubjectFull] => Male
[Type] => general
)
[2] => Array
(
[SubjectFull] => Patient Dropouts
[Type] => general
)
[3] => Array
(
[SubjectFull] => genetic structures
[Type] => general
)
[4] => Array
(
[SubjectFull] => Midazolam
[Type] => general
)
[5] => Array
(
[SubjectFull] => Administration, Oral
[Type] => general
)
[6] => Array
(
[SubjectFull] => Antineoplastic Agents
[Type] => general
)
[7] => Array
(
[SubjectFull] => Pharmacology
[Type] => general
)
[8] => Array
(
[SubjectFull] => chemistry.chemical_compound
[Type] => general
)
[9] => Array
(
[SubjectFull] => Pharmacokinetics
[Type] => general
)
[10] => Array
(
[SubjectFull] => Oral administration
[Type] => general
)
[11] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[12] => Array
(
[SubjectFull] => Cytochrome P-450 CYP3A
[Type] => general
)
[13] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[14] => Array
(
[SubjectFull] => Drug Interactions
[Type] => general
)
[15] => Array
(
[SubjectFull] => Prodrugs
[Type] => general
)
[16] => Array
(
[SubjectFull] => Pharmacology (medical)
[Type] => general
)
[17] => Array
(
[SubjectFull] => Alanine
[Type] => general
)
[18] => Array
(
[SubjectFull] => Cross-Over Studies
[Type] => general
)
[19] => Array
(
[SubjectFull] => Dose-Response Relationship, Drug
[Type] => general
)
[20] => Array
(
[SubjectFull] => CYP3A4
[Type] => general
)
[21] => Array
(
[SubjectFull] => Triazines
[Type] => general
)
[22] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[23] => Array
(
[SubjectFull] => Middle Aged
[Type] => general
)
[24] => Array
(
[SubjectFull] => Prodrug
[Type] => general
)
[25] => Array
(
[SubjectFull] => Crossover study
[Type] => general
)
[26] => Array
(
[SubjectFull] => Fibroblast Growth Factors
[Type] => general
)
[27] => Array
(
[SubjectFull] => Intestines
[Type] => general
)
[28] => Array
(
[SubjectFull] => Receptors, Vascular Endothelial Growth Factor
[Type] => general
)
[29] => Array
(
[SubjectFull] => Brivanib alaninate
[Type] => general
)
[30] => Array
(
[SubjectFull] => Liver
[Type] => general
)
[31] => Array
(
[SubjectFull] => Tolerability
[Type] => general
)
[32] => Array
(
[SubjectFull] => chemistry
[Type] => general
)
[33] => Array
(
[SubjectFull] => Injections, Intravenous
[Type] => general
)
[34] => Array
(
[SubjectFull] => Cytochrome P-450 CYP3A Inhibitors
[Type] => general
)
[35] => Array
(
[SubjectFull] => Female
[Type] => general
)
[36] => Array
(
[SubjectFull] => Metabolic Detoxication, Phase I
[Type] => general
)
[37] => Array
(
[SubjectFull] => business
[Type] => general
)
[38] => Array
(
[SubjectFull] => Half-Life
[Type] => general
)
[39] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, Administered Intravenously and Orally in Healthy Participants
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pamela L. Clemens
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shariq Syed
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Arindam Dhar
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ian Walters
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Eric Masson
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Deanne Lathers
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Georgia Kollia
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 06
[Type] => published
[Y] => 2012
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 00912700
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 52
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => The Journal of Clinical Pharmacology
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |